CorMedix Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)
Revenue
$312M
↑+617.0% +$268Mvs FY2024 (Q1+Q2+Q3+Q4)
Gross Profit
$288M
↑+599.0% +$247Mvs FY2024 (Q1+Q2+Q3+Q4)
Operating profit
$150M
↑+307.0% +$113Mvs FY2024 (Q1+Q2+Q3+Q4)
Net profit
$137M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q1+Q2+Q3+Q4) | FY2024 (Q1+Q2+Q3+Q4) |
|---|---|---|
| Revenue | $312M | $43M |
| COGS | $23M | $2M |
| Gross Profit | $288M | $41M |
| R&D | $19M | $3M |
| SG&A | $0 | $0 |
| D&A | $677K | $132K |
| Other OpEx | $118M | $1M |
| Operating Income | $150M | $37M |
| Interest Exp. | $125K | $26K |
| Other Non-Op | $0 | $37M |
| Pretax Income | $150M | $0 |
| Tax | $13M | $0 |
| Net Income | $137M | $0 |
QuarterCharts · SEC EDGAR data · CRMD · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)